English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Mycotic keratitis, commonly known as fungal keratitis, accounts for approximately 1-44% of all cases of microbial keratitis, depending upon the geographic location (Garg, 2012). Overall, it is more common in tropical and subtropical areas. The genera that commonly cause infection of the cornea include Fusarium, Aspergillus, Curvularia, Bipolaris, and Candida (Qiu et al., 2015). Most of the currently available antifungal medications have limitations, such as poor bioavailability and limited ocular penetration, especially in cases with deepseated lesions (Ansari et al., 2013). To overcome these limitations a number of newer antifungal agents and drug delivery techniques are being tried (Chang and Chodosh, 2011). The antifungal agents used for the treatment of fungal keratitis include three classes: polyenes, triazoles, and echinocandins. Natamycin is a tetraene polyene which has been regarded as the most important agent in the management of fungal keratitis. It acts by binding with ergosterol, which is an essential component in fungal cell wall, and blocks fungal growth. Natamycin is the only antifungal medication approved by U.S. Food and Drug Administration (Arora et al., 2011).

Preformulation considerations of Natamycin and development of Natamycin loaded niosomal formulation